Xenical granted additional indication for treatment of obesity in Korea's children and adolescents
Published: 2004-07-16 06:59:00
Updated: 2004-07-16 06:59:00
Roche Korea's anti-obesity agent, Xenical (orlistat) has bee granted Korea's weight-loss drug for the treatment of obesity in children and adolescents. There are currently no products on the market for the treatment of child obesity, the company notes.
A recent study involving 539 obese child...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
